449 related articles for article (PubMed ID: 34418266)
1. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
[TBL] [Abstract][Full Text] [Related]
2. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
[TBL] [Abstract][Full Text] [Related]
3. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
[TBL] [Abstract][Full Text] [Related]
4. Engineered Cas9 extracellular vesicles as a novel gene editing tool.
Osteikoetxea X; Silva A; Lázaro-Ibáñez E; Salmond N; Shatnyeva O; Stein J; Schick J; Wren S; Lindgren J; Firth M; Madsen A; Mayr LM; Overman R; Davies R; Dekker N
J Extracell Vesicles; 2022 May; 11(5):e12225. PubMed ID: 35585651
[TBL] [Abstract][Full Text] [Related]
5. Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing.
Dubey S; Chen Z; Jiang YJ; Talis A; Molotkov A; Ali A; Mintz A; Momen-Heravi F
Theranostics; 2024; 14(7):2777-2793. PubMed ID: 38773978
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles.
Horodecka K; Düchler M
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34199901
[TBL] [Abstract][Full Text] [Related]
7. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
10. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.
Yan B; Liang Y
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555398
[TBL] [Abstract][Full Text] [Related]
11. High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells.
Steyer B; Carlson-Stevermer J; Angenent-Mari N; Khalil A; Harkness T; Saha K
Acta Biomater; 2016 Apr; 34():143-158. PubMed ID: 26747759
[TBL] [Abstract][Full Text] [Related]
12. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras
McAndrews KM; Xiao F; Chronopoulos A; LeBleu VS; Kugeratski FG; Kalluri R
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34282051
[TBL] [Abstract][Full Text] [Related]
13. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy.
Ahmadi SE; Soleymani M; Shahriyary F; Amirzargar MR; Ofoghi M; Fattahi MD; Safa M
Cancer Gene Ther; 2023 Jul; 30(7):936-954. PubMed ID: 36854897
[TBL] [Abstract][Full Text] [Related]
14. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
Liu C; Zhang L; Liu H; Cheng K
J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
16. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
Xu Y; Liu R; Dai Z
Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
[TBL] [Abstract][Full Text] [Related]
18. Gene Editing by Extracellular Vesicles.
Kostyushev D; Kostyusheva A; Brezgin S; Smirnov V; Volchkova E; Lukashev A; Chulanov V
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33028045
[TBL] [Abstract][Full Text] [Related]
19. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
Cai W; Luo T; Mao L; Wang M
Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]